Sponsored
Jeplus.in
Purchase All Medicines.Get 10% Offer
Pharma Tech
Takeda nets first-in-class advantage on narcolepsy drugâs FDA go-ahead
GlobalData previously flagged Orzeyfulâs approval in narcolepsy as a key Q3 catalyst for pharma due to the drugâs âtransformativeâ potential.
Read Full Article
Pharma Tech
Rethinking sterile product development for manufacturing success
How evolving development priorities are helping organisations build manufacturing knowledge from the earliest stages of development.
Read Full Article
Pharma Tech
Eli Lilly raises 2026 outlook again as Q2 soars past estimates
Reporting 91% growth for Mounjaro, Lilly widened the gap to cardiometabolic rival Novo Nordisk.
Read Full Article
Pharma Tech
Alteogen signs $365m Hybrozyme licensing deal with pharma company
Alteogen has signed an exclusive licensing deal worth up to $365m with a global pharmaceutical company, granting worldwide rights to develop and commercialise a subcutaneous biologic product using its Hybrozyme technology.
Read Full Article
Pharma Tech
China-ready by design: Leveraging NMPAâs new 30âworking day IND pathway
China is becoming a global hub for oncology trials, with the NMPA now offering expedited review pathways for INDs.
Read Full Article
Sponsored content
Featured promotional
News
Latest stories
ET Pharma
Aug 6, 2026, 4:48 PM
After Recall, Sun Pharma Lists its Safe-to-Use Eye-care Drugs
Among the products listed by Sun in the "not affected list" are Cequa, Careprost LS, Gatilox DM, Timolet OD, Eyemist Gel, OCeva injection, Synca and Cafta.
ET Pharma
Aug 6, 2026, 3:18 PM
Novo Nordisk wins Dutch court injunction in semaglutide patent infringement case
"The âCourt found that âCeban infringed Novo Nordisk's supplementary protection certificate (SPC) covering semaglutide," the Danish drugmaker said in âa statement.
Pharma Tech
Aug 6, 2026, 1:11 PM
Takeda nets first-in-class advantage on narcolepsy drugâs FDA go-ahead
GlobalData previously flagged Orzeyfulâs approval in narcolepsy as a key Q3 catalyst for pharma due to the drugâs âtransformativeâ potential.
PharmaShots
Aug 6, 2026, 12:30 PM
Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals for ~$800M
Shots: Ref: Globenewswire |  Image: Alkeus |  Press Release PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com The post Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals for ~$800M appeared first on PharmaShots.
PharmaShots
Aug 6, 2026, 11:30 AM
The US FDA Approves Modernaâs mFLUSIVA Against Seasonal Influenza for Adults Aged 50 or More
Shots: Ref: Moderna |  Image: Moderna |  Press Release PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com The post The US FDA Approves Modernaâs mFLUSIVA Against Seasonal Influenza for Adults Aged 50 or More appeared first on PharmaShots.
PharmaShots
Aug 6, 2026, 11:20 AM
Global Clinical Trials Connect 2027 | May 11-12 | London, UK
As clinical trials become increasingly complex and technology-driven, the need for smarter strategies, stronger collaborations, and patient-centric innovation has never been greater. From decentralized clinical trials and artificial intelligence to advanced data management and evolving regulatory frameworks, the clinical research landscape is undergoing a significant transformation. Global Clinical Trials Connect 2027 aims to bring together⊠The post Global Clinical Trials Connect 2027 | May 11-12 | London, UK appeared first on PharmaShots.
News
Latest industry coverage
Google News
Aug 7, 2026, 3:22 AM
PKU Three Generations of Scientists Develop 20-Years-Old Overlooked Niche Pharmaceutical Track into Thriving Popular Field - 36 Kr
PKU Three Generations of Scientists Develop 20-Years-Old Overlooked Niche Pharmaceutical Track into Thriving Popular Field  36 Kr
Google News
Aug 7, 2026, 1:06 AM
Alteogen Signs Up to $365 Million Hybrozyme Licensing Deal for Subcutaneous Biologic - BioPharma APAC
Alteogen Signs Up to $365 Million Hybrozyme Licensing Deal for Subcutaneous Biologic  BioPharma APAC
Google News
Aug 6, 2026, 11:15 PM
Slotkin, Ricketts Introduce Bipartisan Legislation to Keep Biotech Industry in America, Not China - U.S. Senate (.gov)
Slotkin, Ricketts Introduce Bipartisan Legislation to Keep Biotech Industry in America, Not China  U.S. Senate (.gov)
Google News
Aug 6, 2026, 11:01 PM
Omnicom Wins U.S. Media Account for Ozempic and Wegovy Maker Novo Nordisk - ADWEEK
Omnicom Wins U.S. Media Account for Ozempic and Wegovy Maker Novo Nordisk  ADWEEK
Google News
Aug 6, 2026, 10:33 PM
The Week in Health: Pharma Mega-Merger Talks, Hospital Push - Mexico Business News
The Week in Health: Pharma Mega-Merger Talks, Hospital Push  Mexico Business News
Google News
Aug 6, 2026, 9:52 PM
Lilly, Novo defeat antitrust lawsuit over GLPâ1 drug market - Reuters
Lilly, Novo defeat antitrust lawsuit over GLPâ1 drug market  Reuters
Google News
Aug 6, 2026, 9:48 PM
Amphastar Pharmaceuticals (NASDAQ:AMPH) Posts Better-Than-Expected Sales In Q2 CY2026 - StockStory
Amphastar Pharmaceuticals (NASDAQ:AMPH) Posts Better-Than-Expected Sales In Q2 CY2026Â Â StockStory
Google News
Aug 6, 2026, 9:46 PM
Novo Nordisk Awards U.S.Media Account to Omnicom 08/07/2026 - MediaPost
Novo Nordisk Awards U.S.Media Account to Omnicom 08/07/2026Â Â MediaPost
Google News
Aug 6, 2026, 8:25 PM
BioMarin Pharmaceutical (NASDAQ:BMRN) Delivers Impressive Q2 CY2026, Full-Year Outlook Slightly Exceeds Expectations - financialcontent.com
BioMarin Pharmaceutical (NASDAQ:BMRN) Delivers Impressive Q2 CY2026, Full-Year Outlook Slightly Exceeds Expectations  financialcontent.com
Sponsored placement
Featured promotions
Sponsored
Jeplus.in
Purchase All Medicines.Get 10% Offer